Pierre Wolkenstein
Pierre Wolkenstein is an expert in Dermatology at Hôpitaux Universitaires Henri-Mondor (France). As of October 2026, ScienceLeadR ranks Pierre Wolkenstein in the top 1% of experts worldwide for Neurofibroma, Erythema and Nervous System Neoplasms. Pierre Wolkenstein has authored 705 publications, the most recent in 2026, and is an investigator in 7 clinical trials, 1 of them ongoing. SLR score: 1,920 (community average: 125). How the SLR is computed.
LeadR Profile
Dermatology
Subspecialties: Oncology - Genetics - Neurology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1990 - 2026
Number : 705
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Cherry Angiomas in Individuals With Neurofibromatosis Type 1. PMID 42616496 — cells, neoplasms, skin diseases, odds ratio, prevalence, neurofibromatosis 1, sex, endothelial cells, neurofibromatoses | JAMA Dermatol | 2026 | 0 |
| A standardized imaging and analysis workflow for quantitative evaluation of cutaneous neurofibromas in Nf1-KO mice. PMID 42507669 — cells, research design, neurofibroma, pharmaceutical preparations, workflow, neoplasms, neurofibromatosis 1, therapeutics | PLoS One | 2026 | 0 |
| Outcome measures for cutaneous neurofibromas in NF1: Insights from an international study. PMID 42157600 — sexually transmitted diseases, neurofibroma, skin diseases, photography, laser therapy, esthetics | J Eur Acad Dermatol Venereol | 2026 | 0 |
| Immune landscape characterization of neurofibromas with atypical features in Neurofibromatosis1 reveals PD-1 and the Tim-3/Galectin-9 pathway as potential therapeutic targets. PMID 42071244 — cells, neurofibroma, lymphocytes, galectins, macrophages, neoplasms, neurofibromatosis 1, nerve sheath neoplasms, therapeutics, nervous system diseases, neurilemmoma | Acta Neuropathol Commun | 2026 | 0 |
| Phenotype of neurofibromatosis 1: a comparison study between NF1 mutant mice and humans. PMID 42067126 — phenotype, neurofibromatosis 1, neurofibromatoses, dermatology | J Invest Dermatol | 2026 | 0 |
Clinical Studies 7
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic Inoperable Plexiform Neurofibromas NCT04924608 — neurofibroma, safety, capsules, neurofibromatosis 1, neurofibromatoses, neurofibroma, plexiform | Phase 3 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map